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Arcana Institute, Cracow, Poland, 2 Novo Nordisk Pharma Poland, Warsaw, Poland OBJECTIVES: To compare cost-utility of detemir and NPH insulin in intensive insulin therapy (IIT) of type 1 diabetes patients, cost-utility of detemir and NPH insulin in basal-bolus IIT or added to oral antidiabetes treatment in type 2 diabetes. To estimate the impact of insulin detemir reimbursement on the budget (BIA) of the National Health Fund in Poland. METHODS: Cost-utility analysis from payers' (Polish National Health Fund and patient) perspective in lifetime horizon was conducted using CORE Diabetes Model. The effectiveness data were derived from clinical studies. The model default values and experts' opinion served as data sources for resource use. BIA: Two scenarios were compared: before and after reimbursement of insulin detemir with reimbursement limit equal to the drug price. Population of patients treated with insulin detemir was assumed to consist of type 1 and type 2 patients with documented episodes of severe hypoglycaemia, undergoing IIT (with use of standard basal insulin NPH). RESULTS: CUA: Insulin detemir in type 1 and type 2 diabetes patients is more costly and more effective than NPH insulin in terms of patients' life expectancy and quality adjusted life years (QALYs) gained-cost per QALY gained is: PLN161,138 (€47,512) in type 1 diabetes treatment; PLN603,107 (€177,829), assuming use of basalbolus intensive insulin therapy in type 2 diabetes; PLN72,583 (€21,401), assuming use of long-acting insulin with oral antidiabetes drugs in type 2 diabetes. A Predicted number of patients annually treated with insulin detemir amounts to 6 736. In case of insulin detemir reimbursement yearly public payer's (NHF) expenditures for long-acting insulins used in intensive insulin therapy would increase by PLN 6,1mln (€1,8mln), i.e. 20% compared to a current situation. CONCLUSIONS: Type 1 and type 2 diabetes treatment with insulin detemir offers an improvement of patients' quality of life, being more costly than standard intensive insulin therapy with NPH. Results of the analysis indicate that sitagliptin/metformin treatment is more effective and more expensive than strategy with metformin/ glipizide. ICER is below the acceptable threshold (83,239 PLN), therefore treatment with SIT can be considered as cost-effective.
PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE
Misurski DA 1 , Fabunmi R 2 , Boye KS 1 , Lage MJ 3 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Amylin Pharmaceuticals, San Diego, CA, USA, 3 HealthMetrics Outcomes Research, Groton, CT, USA OBJECTIVES: Compare costs among patients with type 2 diabetes (T2D) treated with exenatide or insulin glargine. These are injectable agents typically used after failure on oral antidiabetic agent(s) METHODS: Data from September 2004 to September 2007 were obtained from a large retrospective claims database. Intent-to-treat cohorts of insulin-naïve adults diagnosed with T2D who initiated therapy on either exenatide (N = 4090) or insulin glargine (N = 1660). Individuals were not allowed to use the other medication or other insulin in the one-year follow-up period. Annual total medical costs and total diabetes related medical costs were estimated using stepwise multivariate regressions. Major cost components were also examined using either stepwise multivariate regressions or a two-part model that controlled for the probability of using the service. Smearing estimates were used to transform estimated log costs into costs. The analyses controlled for the potential impact of patient demographics, general health, prior resource use, comorbidities, and timing of treatment initiation. RESULTS: Initiation with exenatide compared to insulin glargine, was associated with significantly lower total direct medical costs ($19,293 vs $23,782, p < 0.001) and total diabetesrelated medical costs ($7,833 vs $8,536, p < 0.0001). Initiation of therapy with exenatide compared to insulin glargine was also A500 Abstracts
